Pricing Log in Create free account
Saturday 7 November 2026 Export CBUS’s income statement to Excel — free account

Cibus, Inc.

CBUS Healthcare Biotechnology

Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024.

Revenue
+6.54%
EPS
+52.5%
Free cash flow
+31.6%
Total debt
−62.1%

Quarter to June 2026, against a year earlier

1.17 0.03 +2.63%
Market cap
$87.1M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
3/9
Altman Z
−4.83
Beneish M
−4.25
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 38.91%

Capital & Financial Ratios $m

Size
Market Cap 87.13
Revenue ttm 4.35
Net income ttm (99.62)
Free cash flow ttm (46.28)
Net debt Q (20.38)
Valuation
P/E 0.00
Forward P/E (0.89) (negative: loss-making)
Price / sales 20.66 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 6.07 (above 6: high)
Financial health
Current ratio Q 1.62 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1.36)
Growth
Revenue growth Q +6.54% (above 0%: growing)
Operating income growth Q +27.98% (above 0%: growing)
EPS, this year +69.54% (at or above 15%: strong)
EPS, next year A +24.80% (at or above 15%: strong)
Revenue, next year A +42.76% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +51.36% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 16.2×, against a ten-year median of 21.0×; over the ten years it ranged from −0.2× in 2022 to 1,965× in 2019.
P/S against its own 10 years 41.02%
10-year low 10-year high
P/B against its own 10 years 74.67%
10-year low 10-year high
EV/Sales against its own 10 years 39.59%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 33 14 10 20
Receivables 1 1 1 1
Inventory — — — —
Other — — — —
35 17 12 23
2023 2024 2025 Q'26
Payables 6 6 8 6
ST’ Debt — — — —
Other 1 3 0 0
21 20 17 14

Compound Annual Growth %

10y 5y 3y
Sales 11.08% (31.34%) 185.12%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (1.05%) (9.95%) 44.51%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.26 Actual −0.29

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.41 −0.44 Miss by 0.03
Q4 FY25 −0.43 −0.42 Beat by 0.01
Q1 FY26 −0.35 −0.33 Beat by 0.02
Q2 FY26 −0.26 −0.29 Miss by 0.03
Q3 FY26 −0.27 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.33) (0.29) — — —
’25 (1.34) (0.61) (0.44) (0.59) (2.78)
’24 (1.12) (1.14) (7.63) (0.87) (10.83)
’23 (5.45) (3.05) (1.59) (21.86) (25.95)
’22 (6.50) (2.50) (6.50) (3.00) (18.50)
’21 (13.50) (6.50) (10.00) (9.00) (39.00)
’20 (17.00) (16.50) (14.50) (18.50) (66.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 2 1 — — —
’25 1 1 1 1 4
’24 1 1 2 1 4
’23 0 0 0 1 2
’22 0 0 0 0 0
’21 4 12 8 2 26
’20 2 2 5 14 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (9) — — —
’25 (12) (14) (12) (13) (51)
’24 (13) (17) (14) (14) (58)
’23 (2) (12) (15) (17) (46)
’22 (6) (5) (4) (4) (19)
’21 (9) (2) (3) (4) (19)
’20 (12) (13) (5) (13) (44)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (9) — — —
’25 (12) (14) (12) (14) (51)
’24 (14) (17) (14) (14) (59)
’23 (2) (12) (18) (17) (51)
’22 (7) (6) (5) (4) (21)
’21 (10) (2) (3) (4) (19)
’20 (13) (14) (6) (13) (45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 1 0 7 24 26 0 2 4 4 4 +27.8% 5 12 48 +135.5%
Gross margin, % 49.87 100.00 100.00 (27.19) (47.28) (9.89) 100.00 100.00 100.00 100.00 100.00 +50.1 pt
EBT (12) (26) (28) (40) (45) (29) (17) (338) (283) (132) (100) +30.4%
EBT margin, % (3,029.07) (5,114.17) (11,820.76) (542.93) (187.98) (112.36) (10,758.60) (18,582.44) (6,632.66) (3,632.10) (2,291.35) (603.0) pt
Net income (12) (26) (28) (40) (45) (29) (17) (338) (283) (132) (100) +30.4%
Per share, $
Per share, $ Revenue 1.02 1.10 0.38 11.12 35.20 34.67 0.17 0.18 0.18 0.08 0.06 (24.7%)
Earnings (30.83) (56.00) (45.50) (60.50) (66.00) (39.00) (18.50) (25.95) (10.83) (2.78) (1.65) (23.5%)
Cash flow (23.56) (27.61) (32.92) (48.70) (64.45) (25.10) (21.05) (4.48) (2.50) (1.11) (0.60) (28.8%)
Capex (26.59) (1.68) (3.01) (4.53) (2.64) (0.66) (1.65) (0.42) (0.03) (0.01) 0.00 (57.3%)
Free cash flow (50.16) (29.29) (35.93) (53.22) (67.09) (25.76) (22.70) (4.90) (2.53) (1.12) (0.60) (34.5%)
Book value 33.47 124.11 152.19 95.27 54.42 18.86 7.86 28.45 3.97 0.48 0.19 (37.6%)
Shares, m 0 0 1 1 1 1 1 10 23 46 60 +69.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 20.73 1,068.87 1,347.02 31.52 5.99 3.07 38.97 104.23 15.15 21.88 20.66 265.7
P/B 1.29 9.45 3.40 3.68 3.88 5.65 0.85 0.65 0.70 3.65 6.07 3.3
EV/Sales 15.39 977.30 1,025.21 25.98 5.59 3.21 105.11 87.14 19.37 19.45 16.20 228.4
EV/FCF (0.61) (36.60) (10.97) (5.43) (2.93) (4.32) (0.79) (3.13) (1.40) (1.38) (1.52) (6.8)
Cash, $m
Cash, $m Operating cash flow (9) (13) (20) (32) (44) (19) (19) (46) (58) (51) (46) +20.8%
Capex (10) (1) (2) (3) (2) 0 (2) (4) (1) (1) 0 (27.5%)
Free cash flow (20) (14) (22) (35) (45) (19) (21) (51) (59) (51) (46) +11.2%
Balance, $m
Balance, $m Working capital 3 53 89 56 33 10 2 14 (3) (5) 9 n/m
Net debt (5) (47) (76) (41) (10) 3 10 (32) 17 20 (20) n/m
Shareholders’ equity 13 57 93 63 37 14 7 293 92 22 15 +5.8%
Returns, %
Returns, % ROA (56.72) (58.52) (29.22) (38.29) (59.22) (58.10) (56.67) (94.43) (56.21) (38.80) (29.77) +17.9 pt
ROIC (93.51) (147.06) (100.70) (113.98) (101.92) (105.87) (81.50) (76.24) (147.93) (145.89) 0.00 (52.4) pt
ROE (64.67) (73.60) (36.98) (50.82) (90.23) (114.49) (158.12) (178.00) (130.38) (222.98) (219.97) (158.3) pt
People
People Employees 27 35 50 75 59 55 48 183 159 118 — +17.8%
Revenue/emp, $m 0.01 0.01 0.00 0.10 0.40 0.47 0.00 0.01 0.03 0.03 — +8.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Cibus, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ICCC ImmuCell Corporation $90.4M 117× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93% Compare
SEER Seer, Inc. $90.3M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%) Compare
RTSN Retension Pharmaceuticals, Inc. $89.3M — — — — — — — Compare
CBUS Cibus, Inc. $87.1M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%)
PLYX Polaryx Therapeutics, Inc. $86.7M — (loss-making) — — n/m −93.09% (below 0%: shrinking) — 0.00% Compare
MIST Milestone Pharmaceuticals Inc. $86.2M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
VTVT vTv Therapeutics Inc. $86.0M — (loss-making) — (loss-making) +409,222.22% (above 0%: growing) n/m −124.59% (below 0%: shrinking) 100.00% 0.00% Compare
RLYB Rallybio Corporation $84.5M 3.3× — (loss-making) 0.00% n/m +65.25% (above 0%: growing) 100.00% 0.00% Compare
EQ Equillium, Inc. $84.3M — (loss-making) — (loss-making) −52.32% (below 0%: shrinking) n/m −38.67% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $86.5M — — −11.71% — −38.67% 97.14% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 April 2026

Ownership

Directors and executive officers, together 29.91%
Rory Riggs 23.74%
FMR LLC 9.59%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cibus, Inc. (CBUS) Latest News

28 Sep

Impact 4 · · GlobeNewswire

17 Aug

Impact 4 ·
Impact 4 ·

14 Aug

Impact 4 · · Moby
Impact 4 ·

13 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

21 Jul

Impact 4 ·
Impact 4 ·

14 Jul

Impact 4 ·

17 Jun

Impact 4 ·

8 Jun

Impact 4 · · GlobeNewswire

15 May

Impact 3 · · Moby
Impact 3 · · GuruFocus.com

14 May

Impact 3 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

4 May

Impact 4 · · GlobeNewswire

26 Mar

Impact 4 · · GlobeNewswire

25 Mar

Impact 3 · · GlobeNewswire

18 Mar

Impact 4 · · Moby
Impact 4 · · MarketBeat

17 Mar

Impact 4 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · Zacks
Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

6 Feb

Impact 4 · · GlobeNewswire

29 Jan

Impact 3 · · GlobeNewswire

28 Jan

Impact 3 · · GlobeNewswire
stockrow.com/CBUS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com